Voliphage-M 500mg/0.3mg Tablet SR
Marketer
Franco-Indian Pharmaceuticals Pvt Ltd
Salt Composition
Metformin (500mg) + Voglibose (0.3mg)
Overview Voliphage-M 500mg/0.3mg Tablet SR
Diabeta-Comb 500mg/0.3mg Extended-Release Tablets are classified as antidiabetic medications. This dual-action formulation treats type 2 diabetes in adults by regulating blood glucose. Diabeta-Comb should be ingested with meals, consistently at the same time daily for optimal efficacy. Dosage is determined individually by your physician and may be adjusted based on blood sugar monitoring. Continued use is crucial, even with controlled blood sugar, as abrupt cessation can elevate glucose levels, potentially leading to complications including nephropathy, retinopathy, neuropathy, and peripheral vascular disease. This medication is one component of a comprehensive diabetes management plan encompassing diet, exercise, and weight management as directed by your healthcare provider. Lifestyle modifications significantly impact diabetes control. Potential side effects, such as nausea, altered taste perception, appetite suppression, flatulence, abdominal discomfort, diarrhea, and dermatological reactions, are generally transient and self-limiting. Persistent or concerning side effects warrant medical consultation. Your doctor can offer management strategies or treatments for troublesome side effects. This medication is contraindicated in individuals with type 1 diabetes, diabetic ketoacidosis, or severe hepatic or renal impairment. Prior heart disease should be disclosed to your physician before initiating treatment. Pregnant or lactating women must seek medical advice before use. Regular blood glucose monitoring is essential, and your doctor may order blood tests to assess blood cell counts and liver function.
Primary Ingredients of Voliphage-M 500mg/0.3mg Tablet SR
No text provided to rephrase.
Uses of Voliphage-M 500mg/0.3mg Tablet SR
Managing type 2 diabetes
Major Benefits of Voliphage-M 500mg/0.3mg Tablet SR:
Consume this medication precisely as your physician directs, adhering to the prescribed dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Administer Voliphage-M 500mg/0.3mg Extended-Release Tablets with a meal.
Common Side effects of Voliphage-M 500mg/0.3mg Tablet SR:
- Flatulence
- Diarrhea
- Abdominal pain
- Vomiting
- Decreased appetite
How to use Voliphage-M 500mg/0.3mg Tablet SR:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the entire tablet without chewing, crushing, or breaking it. Consume the Voliphage-M 500mg/0.3mg Extended-Release tablet with a meal.
How Voliphage-M 500mg/0.3mg Tablet SR works:
Extended-release Voliphage-M tablets (500mg/0.3mg) contain a dual antidiabetic formulation.
SAFETY ADVICE
AlcoholUNSAFE
Combining Voliphage-M 500mg/0.3mg Tablet SR with alcohol is unsafe.
PregnancyCONSULT YOUR DOCTOR
Extended-release Voliphage-M 500mg/0.3mg tablets may pose risks during pregnancy. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the potential advantages against any risks prior to prescription. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
The extended-release Voliphage-M 500mg/0.3mg tablet is likely unsafe for breastfeeding mothers. Scant evidence in humans indicates potential drug transfer to breast milk, posing a risk to the infant.
DrivingSAFE
Extended-release Voliphage-M 500mg/0.3mg tablets typically have no impact on driving ability. Nevertheless, patients should be aware of the potential for low blood sugar (hypoglycemia) if this medication is taken concurrently with other diabetes treatments like sulfonylureas, insulin, or repaglinide.
KidneyCAUTION
Exercise caution when administering Voliphage-M 500mg/0.3mg SR tablets to individuals with impaired renal function; dosage modification may be necessary. Consult a physician for guidance. Voliphage-M 500mg/0.3mg SR tablets are contraindicated in patients exhibiting severe kidney disease. Routine monitoring of kidney function is recommended during treatment with this medication.
LiverCONSULT YOUR DOCTOR
Insufficient data exists regarding the administration of Voliphage-M 500mg/0.3mg sustained-release tablets to individuals with hepatic impairment. Physician consultation is advised.
What if you forget to take Voliphage-M 500mg/0.3mg Tablet SR :
Should you forget to take a Voliphage-M 500mg/0.3mg Tablet SR, administer it immediately upon remembering. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Voliphage-M 500mg/0.3mg Tablet SR
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Diabetes Treatment |
3,018 People bought this recently